TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06065774
Drug: The Laterally Closed Tunnel Technique with collagen matrix mucograft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene.
Study: NCT04683640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral Placebo for 4 weeks
Study: NCT05863442
Drug: Soliris 300 MG in 30 ML Injection
Normalized name: Soliris 300 MG in 30 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT05863442
Drug: TUR03 300 MG in 30 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational medicinal Product, eculizumab - Turgut
Study: NCT05478109
Drug: [14C]XZP-3287
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg suspension containing 50µCi of \[14C\] XZP-3287
Study: NCT06611514
Drug: Prasterone (DHEA)
Normalized name: prasterone (DHEA)
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prasterone 6.5 mg vaginal tablets
Study: NCT04975438
Drug: GSK1070806
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1070806 will be administered
Study: NCT04975438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered
Study: NCT06137469
Drug: Acetaminophen/SHR20004
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR20004 was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
Study: NCT06137469
Drug: Acetaminophen/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
Study: NCT05972083
Drug: Analgesia management; group S and C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study: NCT05203315
Drug: Duobrii 0.01 % / 0.045 % Topical Lotion
Normalized name: Duobrii 0.01 % / 0.045 % Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duobrii® lotion (halobetasol propionate \[HP\] and tazarotene \[Taz\] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis, and is classified as a high potency (Class II) corticosteroid.
Study: NCT05203315
Drug: CeraVe, Topical Cream
Normalized name: CeraVe, topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CeraVe cream will be used twice daily (in the morning and again in the evening) by the study participant in conjunction with Duobrii and Hydrocortisone cream.
Study: NCT05895565
Drug: PMG1015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including 3 dose levels: level 1, level 2 and level 3
Study: NCT05895565
Drug: PMG1015 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including 2 dose levels corresponding to PMG1015 level 1 and level 2, with no placebo group set for PMG1015 level 3
Study: NCT06712498
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention
Study: NCT04901975
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every \~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg. Spironolactone, the aldosterone antagonist to be utilized in Specific Aim 2 of this study, is FDA approved, has been on the market for many years and is routinely administered to all types of children with congenital heart disease including SV patients. The choice of which patient this should be administered to is up to the clinician and their patients and therefore, not all SV patients are on this medication.
Study: NCT03994471
Drug: XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght
Approvals — FDA: no, EMA: no, PMDA: no
Description: XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine
Study: NCT05255822
Drug: INNA-051
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid for intra-nasal administration
Study: NCT04910646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without orange peel fermentation
Study: NCT05741346
Drug: BCX9930
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally at 400 mg twice daily (BID)
Study: NCT06098027
Drug: [14C]CS0159
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of 4mg \[14C\]CS0159
Study: NCT06165939
Drug: Intra-articular corticosteroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided intra-articular corticosteroid injection treatment in the shoulder joint (2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine) is performed once for the patient at the first week.
Study: NCT06165939
Drug: hydrodilation with 15% hypertonic dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is 15% hypertonic dextrose (6 ml 50% Dextrose + 2 ml 2% Xylocaine + 12 ml normal saline, totaling 20 ml).
Study: NCT04879368
Drug: Trifluridine/Tipracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
Study: NCT01464762
Drug: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg once daily by mouth for 2 weeks followed by 200mg by mouth three times per week for 22 weeks + individualized background of antibacterial drugs
Study: NCT05712811
Drug: CRYOTHERAPY
Normalized name: cryotherapy wart removal device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
Study: NCT05031351
Drug: Withania somnifera
Normalized name: WITHANIA SOMNIFERA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuclear Factor Kappa Beta Inhibitor
Study: NCT05031351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT05078385
Drug: AGLE-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)
Study: NCT05053308
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PCA(fentanyl) Fentanyl bolus = MME \* 15%
Study: NCT05053308
Drug: Sublingual Tablet
Normalized name: Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.
Study: NCT04766931
Drug: FB2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion
Study: NCT05895773
Drug: Saline spray
Normalized name: Saline Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.9% as a nasal and oropharyngeal spray (Mint flavored) will be applied 4 times per day.
Study: NCT04766931
Drug: FB2001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Study: NCT05077631
Drug: ACD856
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.
Study: NCT05077631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution
Study: NCT05077631
Drug: ACD856 (fed cohort)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
Study: NCT05872347
Drug: SPH4336 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion; Exemestane：Administered by oral.
Study: NCT05192642
Drug: Data on other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real word data
Study: NCT05713279
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, the standard treatment plan (SOC) for COVID-19 in the Department of Respiratory and Critical Care Medicine was used as the best accessible treatment, and the treatment plan principle was based on the latest national guidance document (Expert Recommendations for Clinical Treatment of Severe Novel Coronavirus Infection Caused by Omicron Variant; Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10); Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Trial Fourth Edition)). In this study, the drug flunotinib maleate (FM) 100mg is a class of JAK inhibitors of anti-inflammatory therapy of SOC as standard clinical treatment regimen, and will be used in combination with SOC according to the judgment of the investigator.
Study: NCT06231966
Drug: Combination therapy of high-intensity dose rosuvastatin and ezetimibe
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination therapy of rosuvastatin 20 mg and ezetimibe 10 mg
Study: NCT06231966
Drug: Rosuvastatin monotherapy for treat-to-target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin monotherapy for treat-to-target (LDL cholesterol \<70 mg/dL)
Study: NCT03505346
Drug: 68Ga-NODAGA-E[c(RGDyK)]2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
Study: NCT06371482
Drug: Chemotherapy drug of EP regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide: 80-100mg/m², intravenous infusion, given at week 1, 4, 7, 10, 13, 16, a total of 6 cycles.~Carboplatin: AUC=5-6, intravenous infusion, given at weeks 1, 4, 7, 10, 13, 16, a total of 6 weeks. Or cisplatin: 75-80mg/m2 intravenously, given at weeks 1, 4, 7, 10, 13, 16 for a total of 6 weeks.
Study: NCT06082583
Drug: Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensively Tibetan medicine for 28 days, including Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills and Qiwei Tiexue Pill, dosage of which are 1.5g daily.
Study: NCT06147271
Drug: SGLT2i
Approvals — FDA: no, EMA: no, PMDA: no
Description: A randomized clinical trial of superiority with active control (2 arms), with central randomization to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.
Study: NCT04270877
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with LDN-placebo for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
Study: NCT06055374
Drug: BxC-I17e
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form : solution for injection
Study: NCT06055374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form : solution for injection
Study: NCT05387642
Drug: 10 mg PRAX-114, 20 mg PRAX-114, and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose with a washout period between doses
Study: NCT05387642
Drug: 10 mg PRAX-114 or 20 mg PRAX-114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment for 28 days
Study: NCT06015100
Drug: Inetetamab plus pyrotiniband and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inetetamab plus pyrotiniband and capecitabine
Study: NCT04947501
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.~\*\*\*\*\*\*\* Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr.
Study: NCT04753515
Drug: dexmedetomidine combined with midazolam and remifentanil.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.5 mcg/kg dexmedetomidine over 5 min via separate syringe pumps.
Study: NCT04753515
Drug: propofol combined with midazolam and remifentanil.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.33 mg/kg propoful over 5 min via separate syringe pumps.
Study: NCT04947501
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr.
Study: NCT06302062
Drug: Tumor Associated Lymph node T cell
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least one lymph sample is resected from each participant, then it is separated and cultured ex vivo to expand the population of Tumor Associated Lymph node T cells (FIT003 TAL-T). After lymphodepletion, patients are infused with FIT003 TAL-T.
Study: NCT06302062
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A one-day intravenous injection of cyclophosphamide was administered two days prior to the initial cell transfusion.
Study: NCT05501717
Drug: ALXN2030
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
Study: NCT05501717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
Study: NCT05750745
Drug: Sensodyne Sensitivity & Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensodyne Sensitivity \& Gum toothpaste is containing 0.454% w/w SnF2.
Study: NCT06546449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered oral
Study: NCT06585020
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment regimens containing three molecules, rifampicin, ethambutol, and clarithromycin during the 6 first months of treatment. After having confirmed the presence of all inclusion criteria and the absence of all exclusion criteria, and after having obtained the patient's free and informed consent, the patient will be included and randomized to one of the treatment regimens.
Study: NCT05788926
Drug: TG6050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oncolytic Vaccinia virus containing genes encoding the human interleukin 12 (IL-12) and an anti-CTLA4 antibody administered at different dose.
Study: NCT05691712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC as add-on to the pre-trial background medication.
Study: NCT06696833
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide 1000mg/m2 on days -5 to -3, the infusion dose is adjusted according to the subject's condition
Study: NCT05628116
Drug: XC243 50 mg single
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will receive a single dose of the ID (1 tablet once, 50 mg)
Study: NCT05628116
Drug: XC243 100 mg single
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will receive a single dose of the ID (2 tablets once, 100 mg)
Study: NCT05628116
Drug: Placebo single
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will receive a single dose of the ID (1 or 2 tablets once)
Study: NCT05628116
Drug: XC243 200 mg single-dose food effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets, 200 mg)
Study: NCT05628116
Drug: Placebo single-dose food effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets)
Study: NCT05628116
Drug: XC243 200 mg multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily, 200 mg each)
Study: NCT05628116
Drug: Placebo multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily)
Study: NCT06270719
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study medication will be provided by the sponsor during this study.
Study: NCT04120402
Drug: EP-104IAR 25 mg
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 mL intra-articular injection
Study: NCT04120402
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 mL intra-articular injection
Study: NCT05711628
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05683249
Drug: NRCT-101-SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRCT-101SR is a sustained release formulation. Subjects ≥ 50 kg LBM receive a total of four 500 mg tablets/day and subjects \< 50kg LBM receive a total of four 375 mg tablets per day.
Study: NCT05683249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06017141
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given via injection
Study: NCT04816682
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D
Study: NCT06504875
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1000mg/m2 bid po, d1-d14
Study: NCT04879134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline placebo injection~Other Names:~• Saline
Study: NCT05634213
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once the patient is placed on cardiopulmonary bypass, the product will be injected into the left atrial wall using a 27 gauge needle as 4 injections of 200 μL each. Two will be placed in the atrial appendage. The remaining 2 injections will be placed equidistant on the anterior atrial free wall. Each injection will be performed just under the surface of the atrial epicardium over 30 seconds. The needle will stay in place for 10 seconds after the injection to limit back flow from the site of injection.
Study: NCT05392764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching empagliflozin 10 mg
Study: NCT06045806
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT04578613
Drug: ICP-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-022 at a dose of 150mg, QD
Study: NCT06102174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo